-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-518836-36-00
5
2019-10-07
Respiratory Distress Syndrome of preterm babies born < 32 weeks of ges
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid
-
2023-508264-29-00
5
2019-06-11
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2024-513207-13-00
4
2019-03-21
oligometastatic hormone sensitive prostate cancer
-
2022-500451-23-00
5
2019-03-18
Adults with a de novo glioblastoma
-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2024-516628-32-00
5
2019-01-24
Multiple Sclerosis
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-511649-21-00
4
2018-08-01
Advanced cancer of the stomach or the gastroesophageal junction
-
2023-509500-15-00
9
2018-05-03
Adult patients with advanced or metastatic solid tumors
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-516112-21-00
5
2017-11-20
Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-513521-23-00
5
2015-08-19
Prostate Cancer
-
2024-518741-21-00
4
2014-12-23
colon cancer